Invalid Symbol

Stock Research for BIESF

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


BIESF Stock Chart & Research Data

The BIESF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIESF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BIESF Due diligence Resources & Stock Charts

The BIESF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIESF Detailed Price Forecast - CNN Money CNN View BIESF Detailed Summary - Google Finance
Yahoo View BIESF Detailed Summary - Yahoo! Finance Zacks View BIESF Stock Research & Analysis -

Stock Analysis

TradeIdeas View BIESF Trends & Analysis - Trade-Ideas Barrons View BIESF Major Holders - Barrons
NASDAQ View BIESF Call Transcripts - NASDAQ Seeking View BIESF Breaking News & Analysis - Seeking Alpha
Spotlight View BIESF Annual Report - OTC Report View BIESF OTC Short Report -
TradeKing View BIESF Fundamentals - TradeKing Charts View BIESF SEC Filings - Bar Chart
WSJ View Historical Prices for BIESF - The WSJ Morningstar View Performance/Total Return for BIESF - Morningstar
MarketWatch View the Analyst Estimates for BIESF - MarketWatch CNBC View the Earnings History for BIESF - CNBC
StockMarketWatch View the BIESF Earnings - StockMarketWatch MacroAxis View BIESF Buy or Sell Recommendations - MacroAxis
Bullish View the BIESF Bullish Patterns - American Bulls Short Pains View BIESF Short Pain Metrics -

Social Media Mentions

StockTwits View BIESF Stock Mentions - StockTwits PennyStocks View BIESF Stock Mentions - PennyStockTweets
Twitter View BIESF Stock Mentions - Twitter Invest Hub View BIESF Investment Forum News - Investor Hub
Yahoo View BIESF Stock Mentions - Yahoo! Message Board Seeking Alpha View BIESF Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BIESF - Insider Cow View Insider Transactions for BIESF - Insider Cow
CNBC View BIESF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIESF - OTC Markets
Yahoo View Insider Transactions for BIESF - Yahoo! Finance NASDAQ View Institutional Holdings for BIESF - NASDAQ

Stock Charts

FinViz View BIESF Stock Insight & Charts - StockCharts View BIESF Investment Charts -
BarChart View BIESF Stock Overview & Charts - BarChart Trading View View BIESF User Generated Charts - Trading View

Latest Financial News for BIESF

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover
Posted on Friday January 19, 2018

Biotest (BIOG.DE) said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor. The Committee on Foreign Investment in the United States (CFIUS) had initially blocked the sale of the German blood plasma products maker to the Chinese investor Creat Group Corp. The sale of U.S. operations, to an undisclosed buyer and for an undisclosed price, means that Biotest's sale to Creat would proceed.

ADMA: Third Quarter 2017 Financial Results and Corporate Update
Posted on Monday November 13, 2017

By John Vandermosten, CFA NASDAQ:ADMA ADMA Biologics, Inc. (NASDAQ: ADMA) experienced its first full quarter merged with the Biotest Therapy Business Unit (BTBU) and reported 3Q:17 results on November ...

Takeover of plasma firm Biotest by China's Creat hits wall in U.S
Posted on Tuesday November 07, 2017

Chinese investor Creat Group Corp has withdrawn and will rework its application for U.S. approval of a planned takeover of Biotest amid concerns over national security, the German blood plasma products maker said, sending its shares sharply lower. Biotest, whose products are used to treat blood coagulation disorders, auto-immune diseases and immune deficiencies, agreed in April to be taken over by Creat in a 1.3-billion-euro ($1.51-billion) cash deal. It said on Tuesday, however, that the Committee on Foreign Investment in the United States (CFIUS) had national security concerns about the transaction that could not be eased under the planned deal structure.

Chinese Takeover of Biotest Faces U.S. Scrutiny
Posted on Monday October 30, 2017

Chinese investor Creat Group Corp.’s planned takeover of German blood plasma supplier Biotest AG is facing increased scrutiny from the U.S. government, according to people familiar with the matter, potentially ...

Warning: DOMDocument::load(): StartTag: invalid element name in, line: 1 in /home/allsites/ on line 494

Warning: DOMDocument::load(): Extra content at the end of the document in, line: 1 in /home/allsites/ on line 494

Enter a stock symbol to view the stock details.